Skip to content
Peptigraph home
Shop Peptides50% off*

Who should not take retatrutide?

Retatrutide is unapproved, so there is no label with contraindications. The late-stage trials excluded anyone with a personal or family history of medullary thyroid carcinoma or MEN-2.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Retatrutide is unapproved, so there is no label with contraindications. The late-stage trials excluded anyone with a personal or family history of medullary thyroid carcinoma or MEN-2.[1]

Other exclusions in the trial registries

The obesity dose-finding trial excluded people with a major problem with depression or other mental illness within the last 2 years.[2]

The diabetes dose-finding trial excluded people with retinopathy or maculopathy.[3]

The obesity dose-finding trial also excluded documented HIV infection.[2]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?

More on Retatrutide

Side effectsWhat labels and studies report, and what is unknown.Retatrutide overview

Sources

  1. 1A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
  2. 2A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related ComorbiditiesClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  3. 3A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.